LONDON--(BUSINESS WIRE)--Tenpoint Therapeutics (“Tenpoint”), a biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ...
For some degenerative vision disorders, the therapies available don’t restore sight, they mainly slow its decline. To realize this benefit, a patient must receive an eye injection as frequently as ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tenpoint Therapeutics has launched with a $70 million ...
LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their merger to create an entirely new chapter ...
LONDON & SEATTLE, September 08, 2025--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate ...
Leading Pharmaceutical Executive Strengthens Leadership Team as Tenpoint Prepares for the Potential Commercial Launch of BRIMOCHOL™ PF Tenpoint Therapeutics Ltd. (“Tenpoint”), a global, clinical-stage ...
NDA submission includes efficacy and safety data for the first fixed-dose combination therapy from the world’s largest and longest study ever conducted in the presbyopia eye drop category Tenpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback